(ISSN 2577-5790)
OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 4 weeks; Submission to Acceptance: 12 weeks; Acceptance to Publication: 13 days (1-2 days of FREE language polishing included)
Special Issue
Newborn Screening and Inherited Metabolic Disorders
Submission Deadline: January 31, 2024 (Open) Submit Now
Guest Editors
Shibani Kanungo, MD, MPH, FAAP, FACMG, Professsor
Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, United States.
Research Interests: Inborn Errors of Metabolism, Newborn Screening, Genetics, Ethics
Miao He, PhD
Co-Director of Metabolic and Advanced Diagnostics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Research interests: Glycomic Biomarkers; Inherited Metabolic Diseases; Genetic Disorders; Sterols; Overproliferative Inflammatory Skin Disorders
Georgianne Arnold, MD, Professor of Pediatrics
Director, Medical Genetics Clinical Research, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, USA
About the topic:
Newborn Screening, historically initiated more than 60 years old in the United States, has played a vital role in metabolic disorders all over the world. A public health initiative that helped identify a single metabolic disorder, Phenylketonuria (PKU), has now emerged into the most successful public health program now detecting more than 50 conditions. And, includes amino acid disorders, organic acid disorders, fatty acid oxidation disorders, galactose metabolism disorders, biotin metabolism disorder, lysosomal storage disorder, mucopolysaccharidoses, and peroxisomal disorders. Newborn Screening helps diagnose potentially debilitating and even lethal metabolic conditions before any clinical symptom presentations in newborns, as well as in mothers and other members of a family. Prenatal testing options have an equally vital role in diagnosis and management. Newborn Screening has crossed known geographic and political boundaries and is adapted by many countries in all continents. As a result, our understanding of various metabolic disorders’ clinical presentations, treatment approaches and outcomes has evolved. NBS has helped advance molecular technologies in diagnostic approaches as well helped advance innovative treatment approaches like orthotopic liver transplantation, enzyme replacement therapy, hematopoietic stem cell transplantation and gene therapy. Newborn Screening has also emerged as an integrative endeavor between engineering, basic sciences, genetics, clinical medicine, nutritional sciences, pharmaceuticals, public health, public policy, ethics and law.
Publication
Four Decades of Newborn Screening: A Historical Perspective of Laboratory PracticesAbstract The personal experience of 36 years in charge of the Newborn Screening Laboratory in Galicia and the consequences of the recent advancement of sampling from 3 days to 24 hours of the newborn's life are reviewed. The implication in the results of the assay of reducers in urine with the Mandelin reagent and its alternatives is commen [...] |
Newborn Screening for Inborn Errors of MetabolismAbstract Newborn screening can now detect more than 50 disorders, providing early and often life-saving treatment. Inborn errors of metabolism account for the majority of these disorders. This review will consider the more common metabolic disorders identified on newborn screening, including history, technique and management of these disorders. |
Role of Metabolic Nutrition in Newborn Screening and Inherited Metabolic Disordersby
Marie Norris
and
Shibani Kanungo
Abstract The expansion of newborn screening (NBS) encompasses a wide range of inherited metabolic disorders, including disorders of carbohydrate, lipid, and protein metabolism. Effective treatment of these disorders requires comprehensive nutrition and medical management. This review highlights the intricacies of medical nutrition therapy for several [...] |
Whole Genome Sequencing in Era of Newborn ScreeningAbstract After the completion of the human genome project, there have been many advances in the field of genetics. With next generation sequencing, patients can undergo genomic analysis through whole exome or whole genome testing. These comprehensive tests can shorten the diagnostic odyssey and guide medical management and thereby potentially reduce [...] |
Overview of Newborn Screening of Lysosomal Storage Diseases for Pediatric Care ProvidersAbstract Lysosomal storage disorders (LSD) are caused by enzymatic failure to degrade specific cellular byproducts of metabolism within the lysosome. They have a wide range of presentations involving multiple body systems and can manifest from infancy through adulthood. As treatments have become available for many of these disorders, newborn screening [...] |
Secondary Findings of Newborn Screeningby
Hana Alharbi
and
Miao He
Abstract The aim of newborn screening (NBS) program is to detect and manage treatable conditions in the early stages prior to the occurrence of long-term and irreversible sequalae. Phenylketonuria was the first screened disorder, but panels rapidly expanded after the introduction of tandem mass spectrometry technology into the program. Significant [...] |
Newborn Screening for Mucopolysaccharidosis Type I: Past, Present and FutureAbstract Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by a deficiency of the lysosomal hydrolase α-L-iduronidase. MPS I is characterized by a broad range of disease manifestations. This includes devastating neurocognitive and bone manifestations and a short life expectancy in severely affected MPS I patients. Neurocognit [...] |
Relationship between Hearing Loss Risk Factors and Hearing Screening Results in Newborns: A Retrospective Cross-Sectional Studyby
Zahra Iran Pour Mobarakeh
,
Mansoureh Nickbakht
,
Susan Sabbagh
,
Maryam Khorramizadeh
and
Marzieh Amiri
Abstract Congenital hearing loss can have a long-term impact on children’s speech and communication abilities. Early detection and intervention of hearing loss are important in newborns. It is well known that there are several risk factors for hearing loss; however, the relationship between these risk factors and hearing screening tests remains uncer [...] |
Spinal Muscular Atrophy: An OverviewAbstract Spinal muscular atrophy, a leading cause of infant death, is a neurodegenerative disease classified categorically based on age of onset and achieved motor function. The standard method of diagnosis is through molecular genetic testing, ideally through the newborn screen to facilitate early diagnosis and treatment. There are 4 types of spinal [...] |
Newborn Screening in Gaucher Disease: A Bright and Complicated FutureAbstract Gaucher disease (GD) is one of the most common lysosomal storage disorders resulting from biallelic mutations in the GBA1 gene, causing a dysfunction of the lysosomal hydrolase, glucocerebrosidase (acid-β-glucosidase; E.C 3.2.1.45). Clinical manifestations are heterogenous and can include splenomegaly, anemia, and neurolo [...] |
Newborn Screening for Classic Galactosemia: Biochemical Testings, Challenges, and Futureby
Xinying Hong
and
Miao He
Abstract Galactosemia is a group of hereditary disorders of galactose metabolism. Newborn screening for galactosemia type I is mandatory in all states in the US since timely intervention can prevent life-threatening sequela. The biochemical basis, clinical presentation, and potential treatment options for different types of galactosemia are described [...] |
TOP
Vidhi is a Clinical yoga therapist; mentor for yoga therapy training in Krishnamacharya tradition. She holds a MSc in Public health from Kings College London.
Mirela Olympia Fagarasan Palmer
Luigi Fontana, MD, PhD